AFT Pharmaceuticals: 1H23 Result — A Few Sniffles
AFT Pharmaceuticals' (AFT) 1H23 result highlighted ongoing strong underlying revenue momentum which was ahead of our expectations, but this was...
356 Views
AFT Pharmaceuticals (AFT): 1H23 Result – Initial Impressions
AFT Pharmaceuticals (AFT) reported a below expectations 1H23 result with EBIT ex licensing income (underlying EBIT) of NZ$3.4m versus our NZ$5.0m...
369 Views
AFT Pharmaceuticals - H123 focused on portfolio expansion
AFT reported strong post COVID-19 revenue momentum in H123 (NZ$65.8m, 18.4% y-o-y growth), driven by robust organic growth across all regions,...
767 Views
AFT Pharmaceuticals: A Picture of Health; OUTPERFORM
We initiate full coverage of AFT Pharmaceuticals (AFT) with a 12 month target price of NZ$5.00 and an OUTPERFORM rating; we think the market under...
213 Views
AFT Pharmaceuticals - Further studies for Maxigesic IV’s US nod
AFT Pharmaceuticals announced that, along with partner Hyloris Pharmaceuticals, the company will initiate additional studies to address the FDA...
728 Views